- Home
- CELC vs LDI Comparison
CELC vs LDI Comparison
Compare CELC & LDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- LDI
- Stock Information
- Founded
- CELC 2011
- LDI 2010
- Country
- CELC United States
- LDI United States
- Employees
- CELC N/A
- LDI N/A
- Industry
- CELC Medical Specialities
- LDI Finance: Consumer Services
- Sector
- CELC Health Care
- LDI Finance
- Exchange
- CELC Nasdaq
- LDI Nasdaq
- Market Cap
- CELC 391.0M
- LDI 314.1M
- IPO Year
- CELC 2017
- LDI 2021
- Fundamental
- Price
- CELC $10.11
- LDI $1.19
- Analyst Decision
- CELC Strong Buy
- LDI Sell
- Analyst Count
- CELC 6
- LDI 3
- Target Price
- CELC $30.17
- LDI $2.03
- AVG Volume (30 Days)
- CELC 248.4K
- LDI 1.5M
- Earning Date
- CELC 03-31-2025
- LDI 03-11-2025
- Dividend Yield
- CELC N/A
- LDI N/A
- EPS Growth
- CELC N/A
- LDI N/A
- EPS
- CELC N/A
- LDI N/A
- Revenue
- CELC N/A
- LDI $985,646,000.00
- Revenue This Year
- CELC $49.98
- LDI $40.92
- Revenue Next Year
- CELC N/A
- LDI $12.46
- P/E Ratio
- CELC N/A
- LDI N/A
- Revenue Growth
- CELC N/A
- LDI 5.26
- 52 Week Low
- CELC $8.53
- LDI $1.14
- 52 Week High
- CELC $22.04
- LDI $3.23
- Technical
- Relative Strength Index (RSI)
- CELC 43.41
- LDI 26.69
- Support Level
- CELC $9.98
- LDI $1.33
- Resistance Level
- CELC $10.70
- LDI $1.51
- Average True Range (ATR)
- CELC 0.68
- LDI 0.10
- MACD
- CELC 0.06
- LDI -0.03
- Stochastic Oscillator
- CELC 28.38
- LDI 10.05
Stock Price Comparison Chart: CELC vs LDI
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.